| |
| |
| |
| » |
Corporate Overview |
| --------------------------- |
| » |
|
| » |
|
| » |
|
| ------------------------------ |
|
|
| |
| |
| |
| Management, Directors, and Investors |
| |
PhytoCeutica is managed and advised by an experienced group that includes Professor Yung-Chi Cheng (Founder and Chief of Scientific Advisory Board), Robert Tilton, Ph.D. (COO and Vice
President of Science and Technology), and Tah-Mun Su, Ph.D. (Vice President
of Operations & Director of Clinical Department). and Shwu-Huey Liu, Ph.D.
(Senior Director of Pre-clinical and Clinical Studies) The team combines an in-
depth understanding of conventional single molecule development,
pharmaceutical manufacturing, and quality control with an in-depth knowledge
of traditional Chinese medicine. |
| |
PhytoCeutica’s accomplished and experienced Board of Directors is drawn from
a variety of key financial, industrial and academic institutions. Our major investors
are from Taiwan, China, Hong Kong, Singapore, Japan and the U.S. A total of
$21.0M has been invested since PhytoCeutica’s inception in 1999. |
| |
| |
| |
| |
| |
| |
| |
|
